138 Matching Annotations
  1. Aug 2022
    1. Sadoff, J., Gars, M. L., Cardenas, V., Shukarev, G., Vaissiere, N., Heerwegh, D., Truyers, C., Groot, A. M. de, Scheper, G., Hendriks, J., Ruiz-Guinazu, J., Struyf, F., Hoof, J. V., Douoguih, M., & Schuitemaker, H. (2021). Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting (p. 2021.08.25.21262569). https://doi.org/10.1101/2021.08.25.21262569

  2. May 2022
  3. Apr 2022
  4. Mar 2022
  5. Feb 2022
    1. Stegger, M., Edslev, S. M., Sieber, R. N., Ingham, A. C., Ng, K. L., Tang, M.-H. E., Alexandersen, S., Fonager, J., Legarth, R., Utko, M., Wilkowski, B., Gunalan, V., Bennedbæk, M., Byberg-Grauholm, J., Møller, C. H., Christiansen, L. E., Svarrer, C. W., Ellegaard, K., Baig, S., … Rasmussen, M. (2022). Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection (p. 2022.02.19.22271112). medRxiv. https://doi.org/10.1101/2022.02.19.22271112

  6. Dec 2021
    1. A Marm Kilpatrick. (2021, November 24). How do we get broad immunity to SARS-CoV-2 that will protect against future variants? 2 studies (are there more?) suggest that vaccination followed by infection gives broader protection than infection followed by vaccination. @florian_krammer @profshanecrotty @GuptaR_lab https://t.co/rqdf6rE9ej [Tweet]. @DiseaseEcology. https://twitter.com/DiseaseEcology/status/1463391782742335491

  7. Nov 2021
    1. Dhar, M. S., Marwal, R., VS, R., Ponnusamy, K., Jolly, B., Bhoyar, R. C., Sardana, V., Naushin, S., Rophina, M., Mellan, T. A., Mishra, S., Whittaker, C., Fatihi, S., Datta, M., Singh, P., Sharma, U., Ujjainiya, R., Bhatheja, N., Divakar, M. K., … Rakshit, P. (n.d.). Genomic characterization and epidemiology of an emerging SARS-CoV-2 variant in Delhi, India. Science, 0(0), eabj9932. https://doi.org/10.1126/science.abj9932

  8. Oct 2021
    1. Palmer, T., Wallace, L., Pollock, K. G., Cuschieri, K., Robertson, C., Kavanagh, K., & Cruickshank, M. (2019). Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: Retrospective population study. BMJ, 365, l1161. https://doi.org/10.1136/bmj.l1161

  9. Sep 2021
  10. Aug 2021
  11. Jul 2021
  12. Jun 2021
    1. Borobia, A. M., Carcas, A. J., Pérez-Olmeda, M., Castaño, L., Bertran, M. J., García-Pérez, J., Campins, M., Portolés, A., González-Pérez, M., García Morales, M. T., Arana-Arri, E., Aldea, M., Díez-Fuertes, F., Fuentes, I., Ascaso, A., Lora, D., Imaz-Ayo, N., Barón-Mira, L. E., Agustí, A., … Torvisco, J. M. (2021). Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): A multicentre, open-label, randomised, controlled, phase 2 trial. The Lancet, S0140673621014203. https://doi.org/10.1016/S0140-6736(21)01420-3

    1. Parry, H. M., Tut, G., Faustini, S., Stephens, C., Saunders, P., Bentley, C., Hilyard, K., Brown, K., Amirthalingam, G., Charlton, S., Leung, S., Chiplin, E., Coombes, N. S., Bewley, K. R., Penn, E. J., Rowe, C., Otter, A., Watts, R., D’Arcangelo, S., … Moss, P. (2021). BNT162b2 Vaccination in People Over 80 Years of Age Induces Strong Humoral Immune Responses with Cross Neutralisation of P.1 Brazilian Variant. SSRN Electronic Journal. https://doi.org/10.2139/ssrn.3816840

  13. May 2021
    1. Reducing pain at the time of vaccination: WHO Position Paper – September 2015. Weekly epidemiological record. 2015;90(39):505–16 (www.who.int /immunization/policy/position_papers /reducing_pain_vaccination/en/)

    1. Taddio, A., McMurtry, C. M., Shah, V., Riddell, R. P., Chambers, C. T., Noel, M., MacDonald, N. E., Rogers, J., Bucci, L. M., Mousmanis, P., Lang, E., Halperin, S. A., Bowles, S., Halpert, C., Ipp, M., Asmundson, G. J. G., Rieder, M. J., Robson, K., Uleryk, E., … Bleeker, E. V. (2015). Reducing pain during vaccine injections: Clinical practice guideline. CMAJ : Canadian Medical Association Journal, 187(13), 975–982. https://doi.org/10.1503/cmaj.150391

    1. Schmitt, H.-J., Booy, R., Aston, R., Van Damme, P., Schumacher, R. F., Campins, M., Rodrigo, C., Heikkinen, T., Weil-Olivier, C., Finn, A., Olcén, P., Fedson, D., & Peltola, H. (2007). How to optimise the coverage rate of infant and adult immunisations in Europe. BMC Medicine, 5, 11. https://doi.org/10.1186/1741-7015-5-11

    1. Andre, F., Booy, R., Bock, H., Clemens, J., Datta, S., John, T., Lee, B., Lolekha, S., Peltola, H., Ruff, T., Santosham, M., & Schmitt, H. (2008). Vaccination greatly reduces disease, disability, death and inequity worldwide. Bulletin of the World Health Organization, 86(2), 140–146. https://doi.org/10.2471/BLT.07.040089

  14. Apr 2021
  15. Mar 2021
    1. Opel, D. J., Heritage, J., Taylor, J. A., Mangione-Smith, R., Salas, H. S., DeVere, V., Zhou, C., & Robinson, J. D. (2013). The Architecture of Provider-Parent Vaccine Discussions at Health Supervision Visits. Pediatrics, 132(6), 1037–1046. https://doi.org/10.1542/peds.2013-2037

    1. Li, S., Sim, S.-C., Lee, L., Pollack, H. J., Wyatt, L. C., Trinh-Shevrin, C., Pong, P., & Kwon, S. C. (2017). Hepatitis B Screening and Vaccination Behaviors among a Community-based Sample of Chinese and Korean Americans in New York City. American Journal of Health Behavior, 41(2), 204–214. https://doi.org/10.5993/AJHB.41.2.12

  16. Feb 2021
    1. Andrew💙Croxford. (2020, December 3). NEW THREAD: possible development of anti-Syncytin responses after immunization with the SARS-CoV-2 spike protein-coding mRNA vaccines, based on a ‘homologous’ region shared between these proteins. [Tweet]. @andrew_croxford. https://twitter.com/andrew_croxford/status/1334593606196187136

  17. Jan 2021
  18. Sep 2020
  19. Jul 2020
  20. Jun 2020
  21. May 2020
  22. Feb 2020
    1. Annual immunization against influenza (for children and young people with diabetes over the age of 6 months).Immunization against pneumococcal infection (for children and young people with diabetes who need insulin or oral hypoglycaemic drugs).

      T1DM children

      • annual flu vaccine
      • pneumoccocal vaccine
    1. Routine pneumococcal vaccination

      Routine pneumococcal vaccine for:

      Infants - PCV13 - 2m,4m,12m

      Over 65 - PPV23 - one-off

    2. Risk factors

      People at increased risk of pneumococcal disease or complications include those with:

      • Asplenia or splenic dysfunction.
      • Chronic respiratory, heart, kidney, or liver disease.
      • Diabetes requiring insulin or oral hypoglycaemic drugs.
      • Immunosuppression due to a medical condition or treatment.
      • Cochlear implants.
      • Cerebrospinal fluid leaks (including leakage following trauma or major skull surgery).
      • Occupational risks (including welders). For more details, see the section on Risk factors.
    1. For people who are allergic to egg or have had a confirmed anaphylactic reaction to egg

      Contraindications

      • Egg allergy
      • Anaphylaxis
      • Acutely unwell
      • Children who are severely immunocompromised
      • Children with respiratory symptoms
    2. Clinical risk groups in people aged 6 months and older

      Influenza vaccine for >65s and specific risk groups

      • Asplenia or splenic dysfunction.
      • Chronic respiratory, heart, kidney, or liver disease.
      • Diabetes requiring insulin or oral hypoglycaemic drugs.
      • Immunosuppression due to a medical condition or treatment.
      • Chornic neurological disease
      • Pregnant women
      • Children aged 2 to 10 years (but not aged 11 years or older) on 31 August 2019.
      • People living in long-stay residential and nursing homes or other long-stay care facilities (not including prisons, young offender's institutions, or university halls of residence).
      • Close contacts of immunocompromised people, including carers (people who expect to share living accommodation on most days over the winter).
      • All healthcare and social care workers directly involved in patient care, including students, trainees, and volunteers working with patients.